AI assistant
Sending…
UroGen Pharma Ltd. — Director's Dealing 2026
Feb 3, 2026
32312_dirs_2026-02-03_ac1be1e7-53fc-4bc6-830f-d7e009a7fd6b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2026-01-31
Reporting Person: Degnan Chris (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-01-31 | Restricted Stock Units | $ | A | 32609 | Acquired | Ordinary Shares (32609) | Direct |
Footnotes
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029.
More from UroGen Pharma Ltd.
Annual Report
2026
May 27
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 30
Annual Report
2026
Mar 2
Regulatory Filings
2026
Mar 2
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 11